Research Alliance II (Research Alliance II) Common Stock : $150.21 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Research Alliance II Common Stock?

Research Alliance II's quarterly common stock stayed the same from Mar. 2022 ($149.50 Mil) to Jun. 2022 ($149.50 Mil) but then increased from Jun. 2022 ($149.50 Mil) to Sep. 2022 ($150.21 Mil).

Research Alliance II's annual common stock stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($149.50 Mil).

Research Alliance II Common Stock Historical Data

The historical data trend for Research Alliance II's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Research Alliance II Common Stock Chart

Research Alliance II Annual Data

Trend

Dec20

Dec21

Common Stock

149.50

Research Alliance II Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Common Stock	Get a 7-Day Free Trial			149.50	149.50	149.50	149.50	150.21

Research Alliance II Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Research Alliance II (Research Alliance II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Research Alliance Corp II (NAS:RACB) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

3172 North Rainbow Boulevard, Suite 1278, Las Vegas, NV, USA, 89108

Website

https://www.researchalliancecorp.com

Research Alliance Corp II is a blank check company.

Executives

Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Peter Kolchinsky	director, officer: Chief Executive Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Thomas Leggett	director	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Matthew Hammond	director, officer: Chief Investment Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Research Alliance Holdings Ii Llc	10 percent owner	200 BERKELEY STREET 18TH FLOOR, BOSTON MA 02116
Theresa Cameron	director, 10 percent owner, officer: Chief Financial Officer	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Clive Patience	director	C/O RESEARCH ALLIANCE CORP. II, 3172 NORTH RAINBOW BLVD. SUITE 1278, LAS VEGAS NV 89108

Research Alliance II (Research Alliance II) Headlines

From GuruFocus

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

By Business Wire Business Wire • 04-28-2021

Research Alliance Corp. II Will Redeem Public Shares

By Business Wire Business Wire • 11-28-2022